Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -61.24% is 100% below its 5-year average of -30.58%, near the low end of its 5-year range (-61.24%–5.21%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.62% below its 12-month average of -53.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -61.24%.
RETURN ON EQUITY (ROE)
-61.24%
RETURN ON EQUITY (ROE) AVG TTM
-53.43%
RETURN ON EQUITY (ROE) AVG 3Y
-34.62%
RETURN ON EQUITY (ROE) AVG 5Y
-30.58%
RETURN ON EQUITY (ROE) AVG 10Y
-27.69%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-14.62%
CURRENT VS 3Y AVG
-76.87%
CURRENT VS 5Y AVG
-100.23%
CURRENT VS 10Y AVG
-121.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
-52.33%
vs the sector median at left
Denali Therapeutics Inc.
Market Cap
$3.14B
Return on Equity (ROE)
-61.24%
TTM Avg
-53.43%
3Y Avg
-34.62%
5Y Avg
-30.58%
Market Cap
$3.09B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
Market Cap
$3.08B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$3.07B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
Market Cap
$3.37B
Return on Equity (ROE)
N/A
TTM Avg
336.99%
3Y Avg
336.99%
5Y Avg
336.99%
Market Cap
$2.88B
Return on Equity (ROE)
-73.97%
TTM Avg
-48.15%
3Y Avg
-105.34%
5Y Avg
-79.84%
Market Cap
$3.43B
Return on Equity (ROE)
-80.46%
TTM Avg
-68.44%
3Y Avg
592.63%
5Y Avg
329.15%
Market Cap
$3.43B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
Market Cap
$2.82B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.14B | -61.24% | -53.43% | -34.62% | -30.58% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.09B | 12.93% | -48.70% | -135.42% | -110.19% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | -63.59% | -115.27% | -69.35% | -25.98% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.07B | -11.83% | -25.64% | -7.84% | -12.83% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.37B | N/A | 336.99% | 336.99% | 336.99% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -73.97% | -48.15% | -105.34% | -79.84% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -80.46% | -68.44% | 592.63% | 329.15% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.43B | 29.12% | 31.38% | -1.34% | -13.55% |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 29.28% | 27.86% | 4.54% | -12.45% |
| CareDx, Inc (CDNA)vs › | $3.45B | 26.08% | 3.42% | -20.94% | -16.18% |
ROE
-61.2%
ROA
-44.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -61.24% |
| 2026-03-31 | -54.86% |
| 2025-12-31 | -50.56% |
| 2025-09-30 | -53.85% |
| 2025-06-30 | -46.64% |
| 2025-03-31 | -40.43% |
| 2024-12-31 | -34.38% |
| 2024-09-30 | -32.42% |
| 2024-06-30 | -30.26% |
| 2024-03-31 | -9.43% |
| 2023-12-31 | -14.09% |
| 2023-09-30 | -11.13% |
| 2023-06-30 | -10.82% |
| 2023-03-31 | -38.33% |
| 2022-12-31 | -31.27% |
| 2022-09-30 | -37.29% |
| 2022-06-30 | -32.09% |
| 2022-03-31 | -31.13% |
| 2021-12-31 | -30.20% |
| 2021-09-30 | 2.92% |
| 2021-06-30 | 5.21% |
| 2021-03-31 | 5.23% |
| 2020-12-31 | 6.18% |
| 2020-09-30 | -25.81% |
| 2020-06-30 | -42.97% |
| 2020-03-31 | -39.50% |
| 2019-12-31 | -50.04% |
| 2019-09-30 | -15.07% |
| 2019-06-30 | -11.61% |
| 2019-03-31 | -9.98% |
| 2018-12-31 | -6.63% |
| 2018-09-30 | -29.63% |
| 2018-06-30 | -25.12% |
| 2018-03-31 | -16.80% |
| 2017-12-31 | -18.93% |
| 2017-09-30 | -43.83% |
| 2017-06-30 | -43.79% |
| 2017-03-31 | -35.21% |
| 2016-12-31 | -34.05% |
